Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
27.07
+0.70 (2.65%)
At close: Aug 1, 2025, 4:00 PM
27.29
+0.22 (0.81%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Company Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer.
The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Robert W. Duggan |
Contact Details
Address: 601 Brickell Key Drive, Suite 1000 Miami, Florida 33131 United States | |
| Phone | 305 203 2034 |
| Website | smmttx.com |
Stock Details
| Ticker Symbol | SMMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001599298 |
| CUSIP Number | 86627T108 |
| ISIN Number | US86627T1088 |
| Employer ID | 37-1979717 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President and Director |
| Robert W. Duggan | Co-Chief Executive Officer and Executive Chairman |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Dave Gancarz | Chief Business and Strategy Officer |
| Dr. Fong Clow | Chief Biometrics Officer |
| Shelley D. Spray | Chief Education and Brand Officer |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality and Pharmacovigilance Officer |
| Dr. Allen S. Yang M.D., Ph.D. | Chief Medical Officer |
| Dr. Laura Q. M. Chow M.D. | Senior Vice President of Clinical Development |
| Robert LaCaze | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 8-K | Current Report |